๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

PHARMACOKINETICS OF PACLITAXEL ADMINISTERED AS A 3-HOUR OR 96-HOUR INFUSION

โœ Scribed by VINODH R.NANNAN PANDAY; WIM W.TEN BOKKEL HUININK; JAN B. VERMORKEN; HILDE ROSING; FRANCISCA J. KOOPMAN; MARTHA SWART; JAN H.M. SCHELLENS; JOS H. BEIJNEN

Book ID
118770680
Publisher
Elsevier Science
Year
1999
Tongue
English
Weight
121 KB
Volume
40
Category
Article
ISSN
1043-6618

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Clinical pharmacokinetic study of tiazof
Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion
โœ Hiremagalur N. Jayaram; Erzsebet Lapis; Guido Tricot; Patricia Kneebone; Edith P ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 714 KB

Tiazofurin, 2-~-D-ribofuranosylthiazole-4-carboxamide, is cytotoxic to murine and human tumor cells. In earlier Phase-1/41 trials performed in other centers in patients with solid tumors, the drug was given mainly as a I O-min bolus or as a continuous i.v. infusion for 5 days. These protocols were a

A randomized phase 2 trial comparing 3-h
A randomized phase 2 trial comparing 3-hour versus 96-hour infusion schedules of paclitaxel for the treatment of metastatic breast cancer
โœ Stacy L. Moulder; Frankie A. Holmes; Anthony W. Tolcher; Peter Thall; Kristine B ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 168 KB

## Abstract ## BACKGROUND: This study was performed to compare efficacy and toxicity profiles of paclitaxel using 3โ€hour versus 96โ€hour infusion schedules. ## METHODS: Patients with metastatic breast cancer (MBC) were randomly assigned to receive paclitaxel starting at a dose of 250 mg/m^2^ intr